Jacobs Levy Equity Management
KPTI icon

Jacobs Levy Equity Management’s Karyopharm Therapeutics KPTI Stock Holding History

Jacobs Levy Equity Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-18,964
Closed -$246K – 1000
2023
Q4 		$246K Sell
18,964
-137,938
-88% -$1.86M ﹤0.01% 909
2023
Q3 		$3.15M Buy
156,902
+111,778
+248% +$2.51M 0.02% 469
2023
Q2 		$1.21M Sell
45,124
-26,548
-37% -$1.14M 0.01% 665
2023
Q1 		$4.18M Sell
71,672
-78,288
-52% -$3.86M 0.03% 441
2022
Q4 		$7.65M Buy
149,960
+44,458
+42% +$3.08M 0.05% 322
2022
Q3 		$8.64M Buy
105,502
+3,699
+4% +$276K 0.07% 284
2022
Q2 		$6.89M Buy
101,803
+57,569
+130% +$5.28M 0.05% 357
2022
Q1 		$4.89M Buy
+44,234
New +$5.51M 0.03% 431
2021
Q3 		– Sell
-5,417
Closed -$839K – 1087
2021
Q2 		$839K Buy
+5,417
New +$786K 0.01% 775
2021
Q1 		– Sell
-2,835
Closed -$658K – 1072
2020
Q4 		$658K Buy
+2,835
New +$657K 0.01% 815
2020
Q1 		– Sell
-8,834
Closed -$2.54M – 1047
2019
Q4 		$2.54M Buy
8,834
+3,981
+82% +$864K 0.02% 500
2019
Q3 		$700K Buy
+4,853
New +$658K 0.01% 668
2019
Q1 		– Sell
-1,953
Closed -$275K – 995
2018
Q4 		$275K Buy
1,953
+6
+0.3% +$1.01K ﹤0.01% 824
2018
Q3 		$497K Sell
1,947
-2,106
-52% -$582K 0.01% 779
2018
Q2 		$1.03M Buy
4,053
+586
+17% +$145K 0.02% 659
2018
Q1 		$698K Sell
3,467
-80
-2% -$16K 0.01% 716
2017
Q4 		$511K Buy
3,547
+1,907
+116% +$306K 0.01% 746
2017
Q3 		$270K Buy
1,640
+760
+86% +$109K 0.01% 808
2017
Q2 		$119K Sell
880
-636
-42% -$94.1K ﹤0.01% 886
2017
Q1 		$292K Sell
1,516
-1,391
-48% -$223K 0.01% 728
2016
Q4 		$410K Buy
2,907
+247
+9% +$33.4K 0.01% 716
2016
Q3 		$388K Buy
2,660
+240
+10% +$28.8K 0.01% 756
2016
Q2 		$244K Buy
+2,420
New +$314K 0.01% 954

Other funds holding KPTI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jacobs Levy Equity Management's KPTI Position: Q1 2024 in Review

Jacobs Levy Equity Management sold out of Karyopharm Therapeutics (KPTI) in Q1 2024, closing a stake of 18,964 shares — an estimated $246K sold.

Jacobs Levy Equity Management first reported a position in KPTI in Q2 2016 and held it in 23 quarters. The position peaked at $8.64M in Q3 2022. 113 funds tracked by Wall St. Rank hold KPTI as of Q1 2024.

  • Jacobs Levy Equity Management reported no remaining Karyopharm Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 18,964 Karyopharm Therapeutics shares in Q1 2024, an estimated $246K.
  • Jacobs Levy Equity Management first reported a position in Karyopharm Therapeutics in Q2 2016 and held it in 23 quarters.
  • Jacobs Levy Equity Management's Karyopharm Therapeutics position peaked at $8.64M in Q3 2022.
  • 113 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2024.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2024, filed 15 May 2024.